AktieselskabActive
NOVO NORDISK A/S
CVR 24256790Fremstilling af farmaceutiske præparaterUpdated 30. dec. 2024
Revenue
309,1 mia. kr.
Up +6.4%Fiscal year 2025
Gross profit
250,3 mia. kr.
Up +1.8%Fiscal year 2025
Net income
102,4 mia. kr.
Up +1.4%Fiscal year 2025
Profit margin
33,1 %
Fiscal year 2025
Equity
194 mia. kr.
Up +35.2%Fiscal year 2025
Employees
76.343
Up +9.9%2025 average
Key ratios
Fiscal year 2025
- Equity ratio
- 35,7 %
- Return on assets
- 18,9 %
Founded
1931
28. nov. 1931 · 94 years ago
Income statement flow
- Gross margin
- 81 %
- Operating margin
- 41,3 %
- Net margin
- 33,1 %
- Effective tax rate
- 21,5 %
Additional reported detail
- Depreciation and amortisation
- 22 mia. kr.
- 7,1 % of revenue
- Finance income
- 9,7 mia. kr.
- 3,1 % of revenue
- Finance costs
- 6,8 mia. kr.
- 2,2 % of revenue
Income statement flow for fiscal year 2025.
- Revenue: 309,1 mia. kr.. Reported.
- Gross profit: 250,3 mia. kr.. Reported.
- Cost of sales: 58,8 mia. kr.. Reported.
- Operating profit: 127,7 mia. kr.. Reported.
- Sales and distribution: 64,3 mia. kr.. Reported.
- Research and development: 52 mia. kr.. Reported.
- Administration: 6 mia. kr.. Reported.
- Other operating expenses: 300 mio. kr.. Reported.
- Profit before tax: 130,5 mia. kr.. Reported.
- Net finance income: 2,9 mia. kr.. Calculated.
- Net income: 102,4 mia. kr.. Reported.
- Income tax: 28,1 mia. kr.. Reported.
- Address
- Novo Alle 12880 BagsværdDenmark
- Company form
- Aktieselskab
- Industry
- 212000 — Fremstilling af farmaceutiske præparater
- Status
- Active
- Established
- 28. nov. 1931
- Last updated
- 30. dec. 2024